Cargando…

Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib

BACKGROUND: Mucosal melanoma of the oral cavity is a rare entity and accounts for less than 1–3% of all melanomas. Contrary to cutaneous melanoma, primary oral melanoma more commonly harbors mutations in c-KIT. METHODS: A 64-year-old man presented with asymptomatic, multiple, brown-to-black macules...

Descripción completa

Detalles Bibliográficos
Autores principales: Deinlein, Teresa, Wolf, Ingrid H., Rainer, Barbara, Kupsa, Romana, Richtig, Erika, Hofmann-Wellenhof, Rainer, Zalaudek, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567067/
https://www.ncbi.nlm.nih.gov/pubmed/28868012
http://dx.doi.org/10.1159/000477563
_version_ 1783258652990242816
author Deinlein, Teresa
Wolf, Ingrid H.
Rainer, Barbara
Kupsa, Romana
Richtig, Erika
Hofmann-Wellenhof, Rainer
Zalaudek, Iris
author_facet Deinlein, Teresa
Wolf, Ingrid H.
Rainer, Barbara
Kupsa, Romana
Richtig, Erika
Hofmann-Wellenhof, Rainer
Zalaudek, Iris
author_sort Deinlein, Teresa
collection PubMed
description BACKGROUND: Mucosal melanoma of the oral cavity is a rare entity and accounts for less than 1–3% of all melanomas. Contrary to cutaneous melanoma, primary oral melanoma more commonly harbors mutations in c-KIT. METHODS: A 64-year-old man presented with asymptomatic, multiple, brown-to-black macules in the oral cavity. A biopsy was taken and histopathology exhibited mucosal melanoma. In molecular analysis, a c-KIT mutation was proven and a CT scan revealed pulmonary metastases. Due to the multifocality of the lesions, the metastases, and the mutation status, a therapy with imatinib was initiated. RESULTS: After 1 year of therapy, progressive disease in the lung was noticed. Therefore, the therapy was switched to a PD-1 antagonist and a CTL-4 antibody. CONCLUSIONS: Our case suggests that imatinib may be considered as first-line treatment for both locally advanced and distant primary multifocal oral melanoma, for which surgery or radiotherapy of the primary tumor is impossible.
format Online
Article
Text
id pubmed-5567067
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-55670672017-09-01 Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib Deinlein, Teresa Wolf, Ingrid H. Rainer, Barbara Kupsa, Romana Richtig, Erika Hofmann-Wellenhof, Rainer Zalaudek, Iris Case Rep Oncol Case Report BACKGROUND: Mucosal melanoma of the oral cavity is a rare entity and accounts for less than 1–3% of all melanomas. Contrary to cutaneous melanoma, primary oral melanoma more commonly harbors mutations in c-KIT. METHODS: A 64-year-old man presented with asymptomatic, multiple, brown-to-black macules in the oral cavity. A biopsy was taken and histopathology exhibited mucosal melanoma. In molecular analysis, a c-KIT mutation was proven and a CT scan revealed pulmonary metastases. Due to the multifocality of the lesions, the metastases, and the mutation status, a therapy with imatinib was initiated. RESULTS: After 1 year of therapy, progressive disease in the lung was noticed. Therefore, the therapy was switched to a PD-1 antagonist and a CTL-4 antibody. CONCLUSIONS: Our case suggests that imatinib may be considered as first-line treatment for both locally advanced and distant primary multifocal oral melanoma, for which surgery or radiotherapy of the primary tumor is impossible. S. Karger AG 2017-06-22 /pmc/articles/PMC5567067/ /pubmed/28868012 http://dx.doi.org/10.1159/000477563 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Deinlein, Teresa
Wolf, Ingrid H.
Rainer, Barbara
Kupsa, Romana
Richtig, Erika
Hofmann-Wellenhof, Rainer
Zalaudek, Iris
Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib
title Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib
title_full Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib
title_fullStr Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib
title_full_unstemmed Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib
title_short Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib
title_sort treatment of primary and metastatic multifocal mucosal melanoma of the oral cavity with imatinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567067/
https://www.ncbi.nlm.nih.gov/pubmed/28868012
http://dx.doi.org/10.1159/000477563
work_keys_str_mv AT deinleinteresa treatmentofprimaryandmetastaticmultifocalmucosalmelanomaoftheoralcavitywithimatinib
AT wolfingridh treatmentofprimaryandmetastaticmultifocalmucosalmelanomaoftheoralcavitywithimatinib
AT rainerbarbara treatmentofprimaryandmetastaticmultifocalmucosalmelanomaoftheoralcavitywithimatinib
AT kupsaromana treatmentofprimaryandmetastaticmultifocalmucosalmelanomaoftheoralcavitywithimatinib
AT richtigerika treatmentofprimaryandmetastaticmultifocalmucosalmelanomaoftheoralcavitywithimatinib
AT hofmannwellenhofrainer treatmentofprimaryandmetastaticmultifocalmucosalmelanomaoftheoralcavitywithimatinib
AT zalaudekiris treatmentofprimaryandmetastaticmultifocalmucosalmelanomaoftheoralcavitywithimatinib